A 13% death rate in the study arm of a trial of ADC Therapeutics' Zynlonta have sent shares of the Swiss biotech tumbling. The FDA approved the antibody-drug conjugate in 2021 to treat relapsed or ...

Jake Fillery is an Evergreen Editor for GameRant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Birgitta Böckeler, Distinguished Engineer at ...

A security researcher has released exploit code for a Visual Studio Code (VS Code) zero-day vulnerability that allows attackers to steal GitHub authentication tokens by tricking users into clicking a ...

Takeda paid $1.2 billion for ex-China rights to IBI343 and another candidate last year. Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug ...

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Illustration photo of a computer display with the Microsoft Copilot logo, shot in Savigny ...

OpenAI is rolling out the full, limited-release version of GPT-5.5-Cyber—a specialized AI model that outperforms its ...

Mr. Bannon is the chief librarian of the New York Public Library, where he is also the director of branch libraries and education. See more of our coverage in your search results.Encuentra más de ...

Bank security can feel confusing because every account seems to handle it differently. One bank sends a text. Another sends an email. Another asks you to approve a login inside its app. So when ...

The Pentagon on Monday updated its religious affiliation codes after members of the Church of Jesus Christ of Latter-day Saints criticized the list because it did not describe LDS as a "Christian" ...

Before the ASCO presentation, BMS already pushed iza-bren into global testing as a first-line treatment for PD-L1-ineligible triple-negative breast cancer patients. (Angus Liu/Fierce Pharma) A ...